~~<i id='B6AEFDE385'><strike id='B6AEFDE385'><tt id='B6AEFDE385'><pre id='B6AEFDE385'></pre></tt></strike></i>~~

Home» leisure time» Wikipedia

Wikipedia

author：explore 2025-09-30 02:50:05 Page View：9545

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical schools are missing the mark on artificial intelligence
Next article： Activists slam private health insurers over coverage restrictions

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Chamber of Commerce, DOJ clash in court over drug prices

TheU.S.ChamberofCommercesuedtostopanewMedicaredrugpricenegotiationprogramfromgoingintoeffect.AdobeWA

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

New company forms to vet health AI models, root out weaknesses

AdobeThemarketforartificialintelligenceinhealthcareisaboutastransparentasabrickwall.Newtoolsachievei